Currently, there are no data on the prevalence rate of hepatitis B virus (HBV) serologic markers in patients with newly diagnosed inflammatory bowel disease (IBD) in Korea, which is a hepatitis B endemic area.
Currently, there are no data on the prevalence rate of hepatitis B virus (HBV) serologic markers in patients with newly diagnosed inflammatory bowel disease (IBD) in Korea, which is a hepatitis B endemic area.